| p38α (MAPK14) and p38β (MAPK11) are closely related members of the p38 mitogen‑activated protein kinase subfamily within the wider MAPK family, sharing the conserved bilobal serine/threonine kinase fold with an activation loop containing the Thr‑Gly‑Tyr dual phosphorylation motif and acting as stress‑responsive kinases that integrate signals from upstream MAP3Ks and MAP2Ks to control transcriptional programs in immunity, inflammation and cancer. The catalytic cores of p38α and p38β are highly similar, but subtle differences in the activation loop, docking surfaces and C‑terminal tails confer isoform‑specific substrate preferences and regulatory interactions, with p38α generally more abundant and widely expressed and p38β showing distinct expression patterns in female tissue‑specific cancers and other contexts, where its levels can be reduced relative to normal tissue. Upon stimulation by cytokines, Toll‑like receptor agonists, bacterial antigens or other stressors, upstream MAP2Ks MKK3/MKK6 phosphorylate p38α and p38β, enabling these kinases to phosphorylate a range of substrates including transcription factors (ATF2, CREB, MEF2), chromatin regulators (MSK1/2) and other signaling proteins, and bioinformatic interactome analyses across 31 cancer types show that activation of p38 pathways is tightly linked to regulation of cell growth, differentiation, apoptosis and stress responses, with pathway activation levels correlating with both tumor progression and therapeutic responses. In macrophages and other immune cells, p38 activity modulates NF‑κB‑dependent inflammatory gene expression through at least two mechanisms: p38‑dependent phosphorylation and phosphoacetylation of histone H3 at promoters of selected cytokine and chemokine genes increases accessibility of cryptic κB sites and enhances NF‑κB recruitment, and p38–MSK1 signaling can phosphorylate RelA (p65) to boost NF‑κB transcriptional activation and tumor necrosis factor production in response to bacterial antigens. Pharmacologic inhibition of p38 using the selective inhibitor SB203580 attenuates lipopolysaccharide‑induced release of IL‑1β, IL‑6 and TNF‑α in alveolar epithelial models without blocking NF‑κB nuclear translocation, indicating that p38α/β are required for full expression of inflammatory cytokines downstream or parallel to NF‑κB, and tissue studies in crescentic glomerulonephritis show that phosphorylated p38 MAPK and activated NF‑κB co‑localize in crescentic lesions and tubular epithelium, correlate with chemokine (MIP‑1α) levels and inflammatory infiltrates, and decrease during glucocorticoid‑induced convalescence, linking p38–NF‑κB cross‑talk directly to human inflammatory kidney disease. In cancer, interactome‑based analyses reveal that p38α, p38β, p38γ and p38δ pathway activation has tumor‑type‑specific prognostic significance: high p38 pathway activation associates with poor survival in astrocytoma, glioblastoma, thymoma, renal, bladder, esophageal, colorectal, stomach cancers and lung squamous carcinoma, but correlates with better outcomes in HER2‑positive and luminal breast cancers, prostate carcinoma, sarcomas and lung adenocarcinoma, and p38β and p38γ activation in breast cancer is linked to positive responses to taxane and anthracycline therapies, whereas lower p38α/β activation predicts better responses to 5‑fluorouracil in colorectal cancer, highlighting that p38α/β signaling status can serve as a functional biomarker for therapy stratification and selective p38 inhibitor use. |
